Precision medicine player harnesses unique genetic insights to target chronic kidney disease and beyond.
Precision medicine company Maze Therapeutics has filed for an initial public offering (IPO) with the Securities and Exchange Commission. The San Francisco-based company focuses on developing novel, small molecule precision medicines for renal, cardiovascular and related metabolic diseases, including obesity.
Founded in 2017, Maze company reportedly plans to list on the Nasdaq under the ticker symbol MAZE in what could become the first biotech IPO of 2025. According to Reuters, the company reported a profit of $9.03 million for the nine months ended September 30, 2024, compared with a loss of $73.84 million in the same period the previous year.
Prior to the IPO filing, Maze recently completed an oversubscribed $115 million Series D financing round, aimed at advancing its kidney disease candidates.
“Maze has exhibited impressive productivity utilizing its precision medicine-focused platform and variant functionalization approach,” said Dr James Brush of Frazier Life Sciences, which invested in the Series D round. “We believe Maze is well positioned to address key drivers of disease for patients living with CKD, AKD, FSGS, PKU and other metabolic diseases.”
Maze leverages its proprietary platform to identify and characterize genetic variants in diseases, linking them to biological pathways that drive disease in specific patient groups. The company says its platform integrates human genetics data with functional genomics tools and data science technology to identify pharmacologically relevant gene-disease associations. This accelerates its development of small molecule precision medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants.
Maze’s most advanced program is an oral, small molecule inhibitor targeting apolipoprotein L1 (APOL1) for the treatment of APOL1 kidney disease, which recently entered a Phase 2 trial. Another candidate in Maze’s pipeline is an oral drug targeting chronic kidney disease, which entered Phase 1 trials in September.
